Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with low 10%
Quest Diagnostics is adding two new blood tests to help doctors find Alzheimer's disease earlier and easier. This shows the company is growing its medical tools, which could help more patients get checked and might make Quest a busier, more valuable business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.